- Home
- TENB vs AKRO Comparison
TENB vs AKRO Comparison
Compare TENB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENB
- AKRO
- Stock Information
- Founded
- TENB 2002
- AKRO 2017
- Country
- TENB United States
- AKRO United States
- Employees
- TENB N/A
- AKRO N/A
- Industry
- TENB Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- TENB Technology
- AKRO Health Care
- Exchange
- TENB Nasdaq
- AKRO Nasdaq
- Market Cap
- TENB 3.5B
- AKRO 4.5B
- IPO Year
- TENB 2018
- AKRO 2019
- Fundamental
- Price
- TENB $25.98
- AKRO $54.29
- Analyst Decision
- TENB Buy
- AKRO Buy
- Analyst Count
- TENB 17
- AKRO 10
- Target Price
- TENB $39.25
- AKRO $73.56
- AVG Volume (30 Days)
- TENB 1.2M
- AKRO 1.7M
- Earning Date
- TENB 10-29-2025
- AKRO 11-07-2025
- Dividend Yield
- TENB N/A
- AKRO N/A
- EPS Growth
- TENB N/A
- AKRO N/A
- EPS
- TENB N/A
- AKRO N/A
- Revenue
- TENB $974,603,000.00
- AKRO N/A
- Revenue This Year
- TENB $12.22
- AKRO N/A
- Revenue Next Year
- TENB $7.62
- AKRO N/A
- P/E Ratio
- TENB N/A
- AKRO N/A
- Revenue Growth
- TENB 11.05
- AKRO N/A
- 52 Week Low
- TENB $25.94
- AKRO $21.34
- 52 Week High
- TENB $45.45
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- TENB 27.07
- AKRO 68.62
- Support Level
- TENB $27.01
- AKRO $54.10
- Resistance Level
- TENB $28.39
- AKRO $54.37
- Average True Range (ATR)
- TENB 0.87
- AKRO 0.19
- MACD
- TENB -0.22
- AKRO -0.23
- Stochastic Oscillator
- TENB 0.36
- AKRO 87.74
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.